COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders
Reconstituted Board to Revitalize COSCIENS TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) today...
Vaccine
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting...
Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 30,...
Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless...
Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies
Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of...
Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a...
Press Release: Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs
Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs Late-breaking data show infant...
Defence Therapeutics to Attend Bio International Convention in Boston, June 2025
Montreal, Quebec--(Newsfile Corp. - May 28, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the...
Rapid Dose Announces Proposed Equity Private Placement Financing
Burlington, Ontario--(Newsfile Corp. - May 27, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") today announced...
MOBILion Systems to Highlight Customer Use Cases from its MOBIE® Platform and Unveil Plans for their Next Generation Proteomics Platform at ASMS 2025
CHADDS FORD, Pa., May 27, 2025 /PRNewswire/ -- MOBILion Systems, Inc., a leader in separation science innovation, will attend and...
Rapid Micro Biosystems Announces Appointment of Dr. Dafni Bika to Board of Directors
LEXINGTON, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company” or “Rapid Micro”), an...
Mangoceuticals’ Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian Flu
Dallas, TX, May 27, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on...
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with improved pathologic response.ROCHESTER, N.Y., May 27,...
BioNTech to Present Progress Across Diversified Oncology Pipeline at the 2025 ASCO Annual Meeting
MAINZ, Germany, May 27, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data from select pipeline candidates...
IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025
Presentation at ESMO will follow oral 2025 ASCO Annual Meeting presentation highlighting unprecedented survival data from Phase 2 OVATION 2...
IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules
$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of...
Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase
CHATHAM, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company with marketed...
WORK Medical Technology Group LTD Announces Pricing of Registered Offering
Hangzhou, China, May 21, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”),...
Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction
Investigator-initiated Phase 2 trial to evaluate TNX-102 SL’s potential to reduce severity of acute stress reaction (ASR) and frequency of...
GenVivo Highlights Non-Integrating Retroviral Vector Technology with Persistent Payload Expression at the 2025 Retroviruses Meeting
Retroviral vectors that are both non-replicating and non-integrating represent a novel and attractive tool that has potential advantages for gene...